Relay Therapeutics, a Cambridge, Mass.-based biotech company dedicated to developing medicines by leveraging insights from protein motion, completed a $63m Series B financing.
The round was led by BVF Partners, with participation from new investors GV (formerly Google Ventures), Casdin Capital, EcoR1 Capital and Section 32 and existing investors Third Rock Ventures and Alexandria Venture Investments. In conjunction with the funding, Kanishka Pothula, Managing Director at BVF Partners, will join the Board of Directors of Relay Therapeutics.
The company intends to use the funds to advance its pipeline of oncology candidate medicines.
Led by Sanjiv Patel, MD, President and Chief Executive Officer, Relay Therapeutics discovers and develops medicines centered on protein motion. Bringing together scientific advances in structural biology, biophysics, computation, chemistry and biology, the company’s drug discovery engine illuminates the full mobility of a protein and the ways in which protein motion regulates function.
The initial programs are focused on developing therapeutics in oncology.